33 related articles for article (PubMed ID: 22804747)
1. The prevalence and prognostic significance of KRAS mutation in bladder cancer, chronic myeloid leukemia and colorectal cancer.
Ouerhani S; Bougatef K; Soltani I; Elgaaied AB; Abbes S; Menif S
Mol Biol Rep; 2013 Jun; 40(6):4109-14. PubMed ID: 23640097
[TBL] [Abstract][Full Text] [Related]
2. Multiple primary malignant neoplasm: Case report and comprehensive literature review.
Ma XY; Tian K; Sun PF
Front Oncol; 2022; 12():1090634. PubMed ID: 36686734
[TBL] [Abstract][Full Text] [Related]
3. Clinical sequencing identifies potential actionable alterations in a high rate of urachal and primary bladder adenocarcinomas.
Varadi M; Nagy N; Reis H; Hadaschik B; Niedworok C; Modos O; Szendroi A; Ablat J; Black PC; Keresztes D; Csizmarik A; Olah C; Gaisa NT; Kiss A; Timar J; Toth E; Csernak E; Gerstner A; Mittal V; Karkampouna S; Kruithof de Julio M; Gyorffy B; Bedics G; Rink M; Fisch M; Nyirady P; Szarvas T
Cancer Med; 2023 Apr; 12(7):9041-9054. PubMed ID: 36670542
[TBL] [Abstract][Full Text] [Related]
4. Expression of Spred2 in the urothelial tumorigenesis of the urinary bladder.
Oda S; Fujisawa M; Chunning L; Ito T; Yamaguchi T; Yoshimura T; Matsukawa A
PLoS One; 2021; 16(11):e0254289. PubMed ID: 34818323
[TBL] [Abstract][Full Text] [Related]
5. Comparative genomic profiling of glandular bladder tumours.
Maurer A; Ortiz-Bruechle N; Guricova K; Rose M; Morsch R; Garczyk S; Stöhr R; Bertz S; Golz R; Reis H; Bremmer F; Zimpfer A; Siegert S; Kristiansen G; Schwamborn K; Gassler N; Knuechel R; Gaisa NT;
Virchows Arch; 2020 Sep; 477(3):445-454. PubMed ID: 32198650
[TBL] [Abstract][Full Text] [Related]
6. Validation of a Novel, Sensitive, and Specific Urine-Based Test for Recurrence Surveillance of Patients With Non-Muscle-Invasive Bladder Cancer in a Comprehensive Multicenter Study.
Batista R; Vinagre J; Prazeres H; Sampaio C; Peralta P; Conceição P; Sismeiro A; Leão R; Gomes A; Furriel F; Oliveira C; Torres JN; Eufrásio P; Azinhais P; Almeida F; Gonzalez ER; Bidovanets B; Ecke T; Stinjs P; Pascual ÁS; Abdelmalek R; Villafruela A; Beardo-Villar P; Fidalgo N; Öztürk H; Gonzalez-Enguita C; Monzo J; Lopes T; Álvarez-Maestro M; Servan PP; De La Cruz SMP; Perez MPS; Máximo V; Soares P
Front Genet; 2019; 10():1237. PubMed ID: 31921291
[TBL] [Abstract][Full Text] [Related]
7. Management of urachal cancer: A consensus statement by the Canadian Urological Association and Genitourinary Medical Oncologists of Canada.
Hamilou Z; North S; Canil C; Wood L; Hotte S; Sridhar SS; Soulières D; Latour M; Taussky D; Kassouf W; Blais N
Can Urol Assoc J; 2020 Mar; 14(3):E57-E64. PubMed ID: 31348743
[No Abstract] [Full Text] [Related]
8. Next-generation sequencing-based molecular characterization of primary urinary bladder adenocarcinoma.
Roy S; Pradhan D; Ernst WL; Mercurio S; Najjar Y; Parikh R; Parwani AV; Pai RK; Dhir R; Nikiforova MN
Mod Pathol; 2017 Aug; 30(8):1133-1143. PubMed ID: 28548125
[TBL] [Abstract][Full Text] [Related]
9. Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurence and prognostic significance.
Módos O; Reis H; Niedworok C; Rübben H; Szendröi A; Szász MA; Tímár J; Baghy K; Kovalszky I; Golabek T; Chlosta P; Okon K; Peyronnet B; Mathieu R; Shariat SF; Hollósi P; Nyirády P; Szarvas T
Oncotarget; 2016 Jun; 7(26):39293-39301. PubMed ID: 27283768
[TBL] [Abstract][Full Text] [Related]
10. Metastatic signet-ring cell carcinoma of the urinary bladder: A novel management approach to a rare tumour.
Pugashetti N; Yap SA; Lara PN; Gandour-Edwards R; Dall'Era MA
Can Urol Assoc J; 2015; 9(3-4):E204-7. PubMed ID: 26085880
[TBL] [Abstract][Full Text] [Related]
11. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.
Cai G; Wong R; Chhieng D; Levy GH; Gettinger SN; Herbst RS; Puchalski JT; Homer RJ; Hui P
Cancer Cytopathol; 2013 Sep; 121(9):500-7. PubMed ID: 23495083
[TBL] [Abstract][Full Text] [Related]
12. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications.
Italiano A; Hostein I; Soubeyran I; Fabas T; Benchimol D; Evrard S; Gugenheim J; Becouarn Y; Brunet R; Fonck M; François E; Saint-Paul MC; Pedeutour F
Ann Surg Oncol; 2010 May; 17(5):1429-34. PubMed ID: 20049644
[TBL] [Abstract][Full Text] [Related]
13. Mesonephric-like adenocarcinoma of the female genital tract: possible role of KRAS-targeted treatment-detailed molecular analysis of a case series and review of the literature for targetable somatic KRAS-mutations.
Brambs CE; Horn LC; Hiller R; Krücken I; Braun C; Christmann C; Monecke A; Höhn AK
J Cancer Res Clin Oncol; 2023 Nov; 149(17):15727-15736. PubMed ID: 37668797
[TBL] [Abstract][Full Text] [Related]
14. Late recurrence of sigmoid carcinoma mimicking primary vulvar cancer: case report and review of the literature.
Pabuccu E; Tolunay HE; Kocbulut E; Taskın S; Ortac F; Sertcelik A; Sasmaz A; Savas B
Int J Clin Exp Pathol; 2012; 5(6):609-13. PubMed ID: 22949946
[TBL] [Abstract][Full Text] [Related]
15. KRAS mutation is present in a small subset of primary urinary bladder adenocarcinomas.
Alexander RE; Lopez-Beltran A; Montironi R; MacLennan GT; Post KM; Bilbo SA; Jones TD; Huang W; Rao Q; Sen JD; Meehan K; Cornwell A; Miravalle L; Cheng L
Histopathology; 2012 Dec; 61(6):1036-42. PubMed ID: 22804747
[TBL] [Abstract][Full Text] [Related]
16. [Comparative analysis of real-time quantitative PCR-Sanger sequencing method and TaqMan probe method for detection of KRAS/BRAF mutation in colorectal carcinomas].
Zhang X; Wang Y; Gao N; Wang J
Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):77-82. PubMed ID: 24742565
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
